Faberidilactone A, a Sesquiterpene Dimer, Inhibits Hepatocellular Carcinoma Progression Through Apoptosis,...

Area of Science:

• Pharmacology
• Oncology
• Natural Products Chemistry

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide.
• Natural compounds are being explored for novel cancer therapeutics.
• Faberidilactone A is a sesquiterpenoid dimer from Inula japonica with known cytotoxic effects.

Purpose of the Study:

• To investigate the antitumor potential and mechanisms of action of faberidilactone A against HCC.
• To evaluate the efficacy of faberidilactone A in preclinical cancer models.

Main Methods:

• In vitro studies using HepG2 cells to assess apoptosis, ferroptosis, cell cycle arrest, reactive oxygen species (ROS) production, and mitochondrial function.
• Western blot analysis to investigate the modulation of STAT3 and FAK signaling pathways.
• In vivo studies using a zebrafish model to evaluate tumor cell dissemination, metastasis, and anti-angiogenic properties.

Main Results:

• Faberidilactone A induced apoptosis, ferroptosis, cell cycle arrest, increased ROS, and disrupted mitochondrial function in HepG2 cells.
• It inhibited HepG2 cell proliferation by modulating the STAT3 pathway and metastasis via the FAK pathway.
• In vivo, faberidilactone A suppressed HepG2 cell metastasis and exhibited anti-angiogenic effects, with significant inhibition rates at 10 µM.

Conclusions:

• Faberidilactone A demonstrates significant antitumor activity against HCC through multiple mechanisms.
• Its ability to induce cell death, inhibit proliferation and metastasis, and reduce angiogenesis highlights its therapeutic potential for HCC treatment.